Citi Appointed as Depositary Bank for Innate Pharma’s ADR Programme
October 22 2019 - 2:00AM
Business Wire
Citi, acting through Citibank N.A., has been appointed by Innate
Pharma S.A – a commercial stage oncology-focused biotech company –
to act as depositary bank for its American Depositary Receipt
(“ADR”) programme.
Innate Pharma’s American Depositary Shares (“ADS”) trade on the
Nasdaq Global Select Market under the symbol “IPHA”. Each ADS
represents one ordinary share of the company. Innate Pharma’s
underlying ordinary shares are listed and trade on Euronext Paris
under the symbol “IPH”.'
Commenting on the appointment, Dirk Jones, Global Head of Issuer
Services, at Citi said: “We look forward to supporting Innate
Pharma’s Nasdaq listed ADR programme and further expand the
company’s investor outreach through the expertise of our leading
Investor Relations Advisory team and the breadth of our global
equity distribution network.”
For more information on Citi’s Depositary Receipt Services,
visit www.citi.com/dr.
About Innate Pharma
Innate Pharma S.A. is a commercial stage oncology-focused
biotech company dedicated to improving treatment and clinical
outcomes for patients through therapeutic antibodies that harness
the immune system to fight cancer.
Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed
from AstraZeneca, was approved by the FDA in September 2018.
Lumoxiti is a first-in-class specialty oncology product for hairy
cell leukemia (HCL). Innate Pharma’s broad pipeline of antibodies
includes several potentially first-in-class clinical and
preclinical candidates in cancers with high unmet medical need.
Innate has been a pioneer in the understanding of NK cell
biology and has expanded its expertise in the tumor
microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Based in Marseille, France, Innate Pharma is listed on Euronext
in Paris and Nasdaq in the US.
About Citi
Citi, the leading global bank, has approximately 200 million
customer accounts and does business in more than 160 countries and
jurisdictions. Citi provides consumers, corporations, governments
and institutions with a broad range of financial products and
services, including consumer banking and credit, corporate and
investment banking, securities brokerage, transaction services, and
wealth management.
Additional information may be found at www.citigroup.com |
Twitter: @Citi | YouTube: www.youtube.com/citi | Blog:
http://blog.citigroup.com | Facebook: www.facebook.com/citi |
LinkedIn: www.linkedin.com/company/citi
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191021005507/en/
Citi Media Contacts: Belinda Marks +44 (0) 20 7508 3082
belinda.marks@citi.com
Citigroup (NYSE:C)
Historical Stock Chart
From Aug 2024 to Sep 2024
Citigroup (NYSE:C)
Historical Stock Chart
From Sep 2023 to Sep 2024